OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

By partnering with a Dana-Farber antibody engineering expert and leveraging the institute’s cell manufacturing capabilities, cytokine therapeutics company OncoSec is expanding into CAR T cell therapies for solid tumors. The deal highlights how manufacturing-savvy academic centers

Read the full 367 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE